Mark Pruzanski

Mark Pruzanski (board member) discloses dealings in Intercept Pharmaceuticals, Inc. to SEC (Form 4). We count 200 filings; the first trade dates from 9 April 2013 and the latest from 8 November 2023.

Both buying and selling appear: 1 purchase worth €406k, against 88 sales worth €49.4M. Sales outweigh purchases by €49.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 47 share grants and 62 option exercises.

Most recently, on 13 November 2023, the filings show a transaction worth €11.0M in Intercept Pharmaceuticals, Inc. The clock since the last published purchase (9 April 2018) now reads 3,135 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.